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Introduction
AA amyloidosis may develop as a consequence of chronic
inflammatory conditions including inherited periodic
fever syndromes. Mevalonate-kinase (MVK) deficiency
(MKD) appears to be the least frequent underlying condi-
tion after FMF, TRAPS and CAPS. Moreover, amyloido-
sis rarely manifests during childhood. We report a case
of a small child in whom renal biopsy performed because
of the cortico-resistant nephrotic syndrome revealed AA
amyloidosis.
Case Report
A 4-years old Caucasian girl with negative family history
presented with features of nephrotic syndrome in 1/2011.
Over the previous 2 years she had been suffering with
recurrent episodes of unexplained fever with pharyngitis
and lymphadenitis lasting 3 days in 2-4 weekly intervals
and received a putative diagnosis of PFAPA (periodic
fever, adenitis, pharyngitis, aphtae) syndrome. Despite the
increasing frequency of febrile episodes over the last year
investigations aimed at excluding monogenic fevers were
not performed. In early 2011 her IgD was normal, IgA
mildly increased, serum amyoid A (SAA) fluctuated from
normal to 200 mg/l. After the standard corticosteroid (CS)
treatment of nephrotic syndrome had failed to induce
remission after 6 wks, a renal biopsy revealed AA amyloi-
dosis with focal segmental glomerular and vascular
involvement. While genetic analysis was pending, Colchi-
cine was added to the CS treatment followed by daily ana-
kinra injections with good response. After a laborious
genetic screening to exclude mutations causing FMF,
TRAPS and CAPS, following variants in MVK gene were
identified: Mutation V377I and a novel deletion in exon
5 C152WfsX6(c.450_453delGGTG). The latter terminates
the protein six amino acids after the deletion occurs,
effectively making the protein shorter. Within 6 months of
the treatment her proteinuria stabilised at protein/creati-
nine ratio around 23 mg/mmol with normal GFR. So far
there have been no other signs of organ involvement.
Despite ongoing anakinra therapy she continues to have
occasional febrile episodes with temporary increase of pro-
teinuria and SAA which remains below 10 mg/l during
afebrile intervals.
Discussion
MKD/HyperIgD-syndrome has been so far reported in
only a few cases of AA-amyloidosis. Our patient has been
the youngest one to develop this severe complication. The
only other child reported so far was also a compound
heterozygote carrying the genotype G326R/V377I. The
long-term follow-up with careful SAA serial measure-
ments will tell us more about the prognostic significance
of the newly described MVK gene mutation. This case
report also underlines the importance of careful differen-
tial diagnostic re-evaluation of children presenting with
PFAPA-like disease in whom febrile episodes do not show
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